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Sir,
We read with interest the article of Nord et al (2003) who
reported excessive increases in body mass index (BMI) after
chemotherapy in long-term survivors of testicular cancer. We
believe this study presents important data but do not believe that
the data presented fully support the authors’ conclusions. We have
also been interested in the long-term effects of treatment on
testicular cancer patients and have investigated a similar cohort of
680 patients, with at least one remaining testis, treated at our
institution between 1982 and 1992. This consisted of 169 patients
who had orchidectomy as the only treatment, 272 patients treated
by chemotherapy, 158 treated by radiotherapy and 81 treated by
both radiotherapy and chemotherapy. Full details of the study are
reported elsewhere (Huddart et al, 2003). As part of this study, we
investigated the relationship between BMI, clinical- and treatment-
related parameters. Like Nord et al, patients who received
chemotherapy demonstrated a clear increase in weight and
resultant BMI with follow-up (Po0.001), with a mean annual
increase of BMI of 0.264kgm
 2year
 1. Pretreatment BMI was not
available for other groups so data on annual increase for these
patients are not available.
On the basis of our data and those presented by Nord et al,w e
do not believe that treatment received has a direct significant effect
on the long-term BMI. In support of this assertion is the lack of
difference in the follow-up BMI according to treatment received in
both our study (see Table 1) and in the study of Nord et al (Figure
2B in their paper). Nord et al has suggested that after
chemotherapy, there is a higher annual increase of BMI in
chemotherapy patients compared to controls. We do not have
direct control data available on this issue, but we believe on review
of the presented data that this assertion is flawed. If chemotherapy
was to have an effect on annual BMI increase, we find it surprising
that patients treated by orchidectomy only (and not orchidectomy
and radiotherapy) also had a greater annual increase in BMI than
controls. We believe a likely explanation for this discrepancy is
revealed by careful examination of the age distribution of controls
and treated patients. The average age of the control group (at last
follow-up) is 8 years higher than the surgically treated and
chemotherapy-treated patients (even greater at baseline). Our data
(Table 1) and those of Nord et al (their Figures 1A and 2A) show a
clear relationship between age and BMI; both at baseline and on
follow-up. The data presented by Nord et al in Figure 3A confirm
that the rate of increase of BMI is greatest in younger patients, with
no obvious difference between controls and testicular cancer
patients. We see a similar trend in our data. Thus, the greater
change in BMI of chemotherapy-treated patients compared to
controls is likely to be due to the greater rate of change in BMI
between 30 and 44 year patients (age at baseline and follow-up of
Table 1 Analysis of BMI in germ cell tumour patients treated at The
Royal Marsden Hospital according to treatment group, age at last follow-up
and hormonal status
Body mass index (kg/m
2)
N
Median
(IQR)
Mean
(sd)
Significance
a
(v baseline)
Treatment group
Chemotherapy 263 25.9 26.2 P¼0.11
(23.7–28.1) (3.8)
Radiotherapy 156 26.0 27.11 P¼0.947
(24.3–29.6) (4.2)
Chemotherapy/ 78 26.9 26.7 P¼0.998
Radiotherapy (23.7–28.9) (3.8)
Surveillance 164 26.37 28.9 —
(24.4–28.8) (4.4)
Age at last follow-up
o30 years 24.4 26.1
30–39 years 25.7 26.3
40–49 years 26.1 26.6
X50 years 26.7 27.1 P (for trend)¼0.055
Hormone levels
(testosterone)
Normal 538 25.7
(23.6–28.1)
Low 100 28.6 Po0.001
(26.7–31.4)
aAssessed by Mann–Whitney U-test for nonparametric variables. Note that these
data are not normally distributed, so inclusion of mean levels is for comparative
purposes with the data of Nord et al (2003). *Correspondence: Dr RA Huddart; E-mail: roberth@icr.ac.uk
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(age of control group). In support of this is the observation that
patients treated with radiotherapy, who have an age at follow-up
similar to controls, have a similar rate of increase of BMI to
controls (Nord et al, Figure 1A).
This does not exclude important changes occurring in the
BMI of testicular cancer survivors. However, we believe that
these are more likely to be related to the underlying
patient characteristics and the sequelae of orchidectomy. In
our series of patients, we found that 100 out of 638 (15.7%)
had low testosterone levels (p10ngml
 1) at long-term
follow-up. These patients had a significantly higher BMI compared
to those with normal testosterone levels (median BMI of 28.6
compared to 25.7kgm
 2;Po0.001). In total, 88% of patients with
low testosterone have a BMI in the overweight range (X25kg
m
 2) compared to 58% of those with normal testosterone
(Figure 2). When we undertook a linear regression analysis
with age either at last follow-up or at treatment and testos-
terone status (normal vs low) at last follow-up, both signifi-
cantly predicted for increased annual rate of change of BMI
(both Po0.001). A model including age at last follow-up (which
was a more robust predictor than age at treatment) and
testosterone produced a model that predicted 18.6% of the
variation observed. Although this is still a weak model, it is a
stronger predictor of BMI increase than that produced by the
Nord et al model.
The effect on survivors of raised BMI remains unclear. We have
confirmed that there is a significant association between BMI and
blood pressure in our series of testicular survivors (Table 2), but
no association with cardiac events after a median of 10 years of
follow-up (HR 1.01 95% CI 0.94–1.09; P¼0.8) (Huddart et al,
2003).
In conclusion, in testicular cancer survivors, increases in BMI
are associated with age and residual gonadal function, but the
evidence of a direct treatment-related effect is weak at best. An
increased BMI is associated with raised blood pressure but to date
not with cardiac morbidity.
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Table 2 Association of overweight BMI with hormonal status and blood
pressure
Body mass index
o25 X25 P-value
Testosterone status (% of patients)
Normal 41% 58% Po0.001
a
Low 12% 88%
Blood pressure (mmHg
 1)
Systolic (median) 130 140 Po0.001
b
Diastolic (median) 80 90 Po0.001
b
aw
2 test.
bMann–Whitney U-test.
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